Biomarkers for Early Detection of Hematopoietic Malignancies (R21)

The summary for the Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Biomarkers for Early Detection of Hematopoietic Malignancies (R21)
	CFDA Number:	93.393
	CFDA Description:	Cancer Cause and Prevention Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-09-198
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Jun 01, 2009
	Creation Date:	Jun 01, 2009
	Original Closing Date for Applications:	Sep 07, 2012
	Current Closing Date for Applications:	Sep 07, 2012
	Archive Date:	Oct 08, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	$200,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.
Grant Description: Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages research grant applications from institutions/organizations for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA is also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies. Mechanism of Support. This FOA will utilize the NIH exploratory/developmental (R21) grant mechanism and runs in parallel an FOA of identical scientific scope, PA-09-197) that encourages applications under the R01 mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-09-198.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Alliance of Glycobiologists for Detection of Cancer (U01); • Cancer Target Discovery and Development (CTDD) Network (U01); • Community Clinical Oncology Program Research Bases (U10); • Minority-Based Community Clinical Oncology Program Groups (U10); • Community Clinical Oncology Program Groups (U10); • Pilot Studies in Pancreatic Cancer; • CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM; • MOLECULAR TARGETS FOR NUTRIENTS IN PROSTATE CANCER PREVENTION; • Cancer Prevention Research Small Grant Program (R03); • Pilot Studies in Pancreatic Cancer (R03)